Symbolbild · KI-generiert
Cerus Corporation
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Cerus Corporation develops and markets the INTERCEPT Blood System, a pathogen inactivation system for blood products including platelets, plasma and red blood cells. The system is designed to reduce the risk of transfusion-transmitted infections by inactivating pathogens and leucocytes in blood products. The company distributes its technology to blood banks and transfusion centres worldwide.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Cerus Corporation | CERS | NASDAQ | 431 Mio. USD |
| Tilray Brands Inc. | TLRY | TSX | 434 Mio. USD |
| Pacific Biosciences of California, Inc. | PACB | NASDAQ | 435 Mio. USD |
| Prothena Corporation plc | PRTA | NASDAQ | 425 Mio. USD |
| Cabaletta Bio, Inc. | CABA | NASDAQ | 437 Mio. USD |
| Sagimet Biosciences Inc. Series A | SGMT | NASDAQ | 439 Mio. USD |
| K-Bro Linen Inc. | KBL | TSX | 439 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.